Navigation Links
Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
Date:10/14/2008

. Based on the current expected level of receipts and expenditures, the company believes that its cash and cash equivalents are sufficient to support its activities into the fourth quarter of fiscal year 2009. The company will be eligible to receive a minimum milestone payment of $20 million from its U.S. partner, Strativa Pharmaceuticals, in the event that the planned NDA submission results in the company receiving marketing approval for ONCONASE.

Clinical/Regulatory Update

Alfacell has completed patient enrollment in a confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from unresectable malignant mesothelioma (UMM) and reached the required number of evaluable events to conduct the formal statistical analyses required to complete the final sections of the ONCONASE rolling NDA. As the company has previously reported, the results of the preliminary statistical analysis of the data did not meet statistical significance for the primary endpoint of survival in UMM. However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen, a pre-defined primary data set for this sub-group of patients in the trial, which represents a currently unmet medical need. Alfacell has requested a pre-NDA meeting with the Food and Drug Administration (FDA) to discuss the details of the planned NDA submission. The company continues to estimate that the final components of the rolling NDA will be submitted by the end of 2008, and the company plans to present the results of the Phase IIIb trial at an upcoming scientific conference in 2009.

The company has completed enrollment in its Phase I clinical trials for patients suffering from non-small cell lung cancer (NSCLC) and other solid tumors and is planning for a follow-on Phase II clinical trial in NSCLC patients that exhibit resistance to platinum based chemotherapy regimens. Initiation of patient enrollment in this tria
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
2. Alfacell Hires Advisors to Advance Strategic Alternatives
3. Alfacell Receives NASDAQ Delisting Letter
4. Alfacell Receives NASDAQ Non-Compliance Notification
5. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
6. Alfacell Announces Retirement of Chief Executive Officer
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
11. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Chicago, IL (PRWEB) May 22, 2013 Alton ... thetelegraph.com dated May 15, 2013 said that their presence ... help other bed bug sufferers avoid such big spending, My ... bugs inexpensively. , It was said in the report ... an exterminator, MCP related. Apart from that, its employees also ...
(Date:5/22/2013)... CAMBRIDGE, Mass. , May 22, 2013  Moderna ... revolutionary new treatment modality to enable the in ... John Reynders will join Moderna ... Reynders is a proven leader in ... phases of drug development, from discovery to translation, clinical ...
(Date:5/21/2013)... MA (PRWEB) May 21, 2013 ... tracking to reporting eLearning solution using Tin Can ... and dashboard tool. CLD is a leading developer ... and medical device companies worldwide. , Tin ... standard that helps learners and trainers more accurately ...
(Date:5/21/2013)... , May 21, 2013 ... Dialysis and Transplant Association) is the biggest congress in ... replacement therapy. Nearly 10,000 participants are in ... the latest research findings. New pioneering studies have been ... "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA ...
Breaking Biology Technology:Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3
... The ALS Therapy Development Institute (ALS TDI) ... Silicon Valley entrepreneur, to its board of directors. ALS ... mission to discover and develop treatments that effectively slow ... (Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO ) "My ...
... of splitting layered materials to give atom thin "nanosheets" ... of novel two-dimensional nanomaterials with chemical and electronic properties ... energy storage technologies. The collaborative* international research led ... Nanodevices (CRANN), Trinity College Dublin, Ireland, and the University ...
... Van Beek, president and CEO of Van Beek Natural ... dogs and cats, available exclusively through veterinarians. ... containing both probiotics and prebiotics that work together to ... or cat,s GI tract.  Van Beek Natural Science,s formulations ...
Cached Biology Technology:ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors 2New nanomaterials unlock new electronic and energy technologies 2Van Beek Natural Science Announces New Synacore Digestive Support Product 2
(Date:5/21/2013)... have found that a class of pharmaceuticals can both ... The drugs, known as "TSPO ligands," are currently used ... the effects of TSPO ligand in young adult mice ... aged mice when pathology was quite severe," said lead ... Gerontology. "TSPO ligand reduced measures of pathology and improved ...
(Date:5/21/2013)... in pharmacies and health stores, phosphatidylserine is a ... soy. Proven to improve cognition and slow memory ... experiencing memory impairment. Now a team headed by ... Tel Aviv University,s Department of Human Molecular ... improves the functioning of genes involved in degenerative ...
(Date:5/21/2013)... decades, scientists have developed many devices that can reopen ... generally effective, each of these treatments has drawbacks, including ... from MIT analyzes the potential usefulness of a new ... drug-releasing stents, but may pose fewer risks. With this ... for only a brief period, during which it releases ...
Breaking Biology News(10 mins):Drugs found to both prevent and treat Alzheimer's disease in mice 2Common food supplement fights degenerative brain disorders 2Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3
... made significant inroads into uncovering the genetic basis of ... overall obesity and 13 that affect fat distribution. The ... million participants, the largest genetic investigation of human traits ... Investigation of ANthropometric Traits) consortium which consists of ...
... be on the way for millions of people on the ... Scientists have reported a key advance in efforts to develop ... a major nuisance to homeowners and a devastating pest to ... fungus that infects a common weed and found that it ...
... , A drug being developed as a treatment for ovarian ... in some patients in a Phase-II clinical trial, an international ... Dana-Farber Cancer Institute in the USA reported the results of ... poster at the 35th Congress of the European Society for ...
Cached Biology News:Studies provide new insights into the genetics of obesity and fat distribution 2Studies provide new insights into the genetics of obesity and fat distribution 3Progress toward first commercial repellent for East Coast's stinker 2Investigational ovarian cancer drug shows promise against platinum resistant disease 2
... AgarACE Enzyme(a) is a unique agarose-digesting enzyme ... recovery of intact DNA or RNA from ... that low melting point (LMP) agarose melted ... equilibrated to the reaction temperature before hydrolysis. ...
...
... proteins (NMPs) make up the internal structural framework ... functions as DNA replication, RNA synthesis, and hormone ... shown to be highly insoluble in vitro ... releases soluble nuclear matrix proteins that can be ...
Request Info...
Biology Products: